GSK Influenza Update

Leonard Friedland, MD
Vice President, Scientific Affairs and Public Health, Vaccines

GSK’s Global & US Commitment to Influenza
Canada, Germany, Belgium, US Manufacturing

Dresden (Germany)
Rixensart (Belgium)
Leval (Canada)
Philadelphia (US)

influenza vaccines

Fluarix® Quadrivalent Influenza Vaccine
FluLaval® Quadrivalent Influenza Vaccine

GlaxoSmithKline

Marietta (US)
Importance of Timely Delivery to Customer
Improving GSK's Ability to Supply Seasonal Influenza Vaccine

Strains determined by WHO
Calibration of reagents: Start of Formulation
FLU SEASON
PREPARATION FOR NEXT SEASON

CONSISTENCY, MAINTENANCE AND LEARNINGS HELP US PREPARE FOR BOTH SEASONAL AND POTENTIAL FUTURE EPIDEMIC CHALLENGES

2015-16 GSK US Supply of Influenza Vaccine
Fluarix QIV Prefilled Syringe and FluLaval QIV Multi-dose Vial

- QIV Only for the 2015-16 Season
- 32-38 million doses planned for the US
  - 30% INCREASE in supply capacity over 2014-15
  - Final quantities will be based on demand & production capabilities
- On TRACK to start shipment in early August

QIV Only for the 2015-16 Season
32-38 million doses planned for the US
30% INCREASE in supply capacity over 2014-15
Final quantities will be based on demand & production capabilities
On TRACK to start shipment in early August
SHOWS VALUE OF PUBLIC-PRIVATE PARTNERSHIP: Each partner – the U.S. Government, the State of Texas, Texas A&M and GSK bring specific core competencies and resources to the Texas Center project. We believe this will create synergy, innovation and flexibility on behalf of patients and public health.

Global & US Commitment to Patients & Customers

New GSK US Vaccines R&D Center - Rockville, MD

The new US vaccines R&D centre will expand GSK’s efforts to discover and develop novel vaccines across a range of pressing public health threats.

Key late stage development programmes, as well as vaccine discovery and new platform technology development will be led from Rockville.